RSV vaccination effects on heart and lung health in at-risk adults aged 50–59
Official title: Assessment of new recommendations for RSV vaccination in 50-59 year old high risk adults on short- and long-term cardiorespiratory outcomes
Funded at Vanderbilt University Medical Center · NIH-11427018 · Data updated 2026-11-12
A Vanderbilt study will look at how RSV vaccines affect real-world heart and lung health in adults aged 50–59 who have higher risk due to other health conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | August 5, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $818,076 |
| NIH project number | 1R01AI201157-01 |
| Project ID | NIH-11427018 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults aged 50–59 with high-risk chronic conditions who are eligible for RSV vaccination.
✕Less likely to help
Adults without high-risk conditions or those not considering vaccination may see little to no direct benefit.
What this research studies
This project focuses on adults 50–59 with chronic medical conditions to see how receiving an RSV vaccine influences short- and long-term heart and lung function and related outcomes. It will use real-world data to measure vaccine effectiveness against RSV-related lower respiratory tract disease and any long-term respiratory health effects. The study also aims to monitor potential safety signals, including rare adverse events like Guillain–Barré syndrome, in this age group. Results could inform future vaccination guidelines and patient conversations about RSV prevention.
Why it matters
Potential benefit: If successful, the research could clarify how protecting against RSV helps maintain breathing health in at-risk middle-aged adults.
How similar studies have gone: Prior data show RSV vaccination can reduce illness in older adults, but long-term cardiorespiratory effects in 50–59 year olds with risk factors are less certain.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Wu, Pingsheng — Vanderbilt University Medical Center
- Study coordinator: Wu, Pingsheng
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
-
Spatially responsive mass vaccination for urban rabies
A project tests smarter placement of vaccination sites to increase mass canine rabies vaccination in cities.
-
Vaccine failure after Covid-19 vaccination in older adults
This project follows vaccinated older adults to understand who among them still gets Covid-19 and what factors make those outcomes worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.